Stoke Therapeutics, Inc. STOK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.23M-96.1% | $1.4M-93.8% | $10.63M+117% | $13.82M+186% | $158.57M+3,661% | ||
| $39.67M+21.4% | $41.7M+78.0% | $37.7M+69.8% | $25.86M+22.3% | $32.68M+46.1% | ||
| $19.97M+36.3% | $21.15M+64.6% | $16.03M+26.3% | $15.26M— | $14.65M— | ||
| $59.65M+26.0% | $62.84M+73.3% | $53.72M+53.9% | $41.12M+20.3% | $47.33M+45.2% | ||
| $59.65M+26.0% | $62.84M+73.3% | $53.72M+53.9% | $41.12M+20.3% | $47.33M+45.2% | ||
| -$53.42M-148% | -$61.44M-350% | -$43.09M-43.6% | -$27.3M+7.0% | $111.24M+492% | ||
| -857.6%-928pp | -4,382.2%-4,322pp | -405.3%+208pp | -197.6%+410pp | 70.2%+743pp | ||
| $3.4M+17.6% | $3.62M+21.7% | $3.46M-2.3% | $3.79M+2.5% | $2.89M+19.1% | ||
| $3.42M+17.1% | $3.51M+10.5% | $3.47M-3.0% | $3.82M+4.7% | $2.92M+46.0% | ||
| -$50M-144% | —— | -$39.63M-49.9% | -$23.48M+8.6% | $114.16M+533% | ||
| -$0-100% | —— | -$1.28M— | $0— | $1.28M— | ||
| -$50M-144% | -$57.93M-453% | -$38.35M-45.1% | -$23.48M+8.6% | $112.88M+528% | ||
| -802.7%-874pp | -4,132.2%-4,086pp | -360.7%+179pp | -170%+362pp | 71.2%+697pp | ||
| -$0.79-142% | -$0.97-471% | -$0.65-38.3% | -$0.40+13.0% | $1.90+433% | ||
| -$0.79-141% | -$1.00-488% | -$0.65-38.3% | -$0.40+13.0% | $1.95+442% | ||
| 63.1M+6.2% | 59.2M+9.6% | 58.6M+4.0% | 58.4M+4.6% | 59.4M+28.4% | ||
| 63.1M+9.0% | 59.2M+9.6% | 58.6M+4.0% | 58.4M+4.6% | 57.9M+25.1% | ||
| $3.4M+17.6% | $3.62M+21.7% | $3.46M-2.3% | $3.79M+2.5% | $2.89M+19.1% | ||
| -$50.66M-145% | -$57.84M-436% | -$38M-44.8% | -$23.28M+9.4% | $112.93M+529% | ||
| -$658K-1,500% | $97K+131% | $350K+93.4% | $200K+1,433% | $47K+95.8% | ||
| -$658K-1,500% | $97K+131% | $350K+93.4% | $200K+1,433% | $47K+95.8% | ||
| $18K-35.7% | -$110K— | $3K-89.3% | $28K+158% | $28K+107% | ||
| -$53.42M-148% | -$61.44M-350% | -$43.09M-43.6% | -$27.3M+7.0% | $111.24M+492% | ||
| -$52.98M-147% | -$61.03M-365% | -$42.65M-44.8% | -$26.85M+6.7% | $111.72M+502% | ||
| -$52.98M-147% | -$61.03M-365% | -$42.65M-44.8% | -$26.85M+6.7% | $111.72M+502% | ||
| -850.5%-921pp | -4,353.4%-4,295pp | -401.1%+201pp | -194.4%+402pp | 70.5%+730pp | ||
| -$53.42M-148% | -$61.44M-350% | -$43.09M-43.6% | -$27.3M+7.0% | $111.24M+492% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Stoke Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.